Krystal Biotech, Inc. (KRYS)
Sector: Healthcare
Industry: Biological Products, (No Diagnostic Substances)
Country: United States
Exchange: NASDAQ
Market cap: $9.97B
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
Latest financial period: June 30, 2026
Filed with the SEC: August 3, 2026
Estimated earnings date: November 2, 2026
Profit #262 of 1484 companies
| | Jun 26 | Mar 26 | Dec 25 | Sep 25 |
|---|
| ROE/ROA | 82.1% | 81.9% | 81.4% | 82.5% |
Growth #223 of 1484 companies
Payout #1079 of 1484 companies
Safety #111 of 1484 companies
Price #1087 of 1484 companies
